Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis by Yoony YJ Gent et al.
RESEARCH ARTICLE Open Access
Evaluation of the novel folate receptor ligand
[18F]fluoro-PEG-folate for macrophage targeting
in a rat model of arthritis
Yoony YJ Gent1†, Karin Weijers1†, Carla FM Molthoff2, Albert D Windhorst2, Marc C Huisman2, Desirée EC Smith3,
Sumith A Kularatne4, Gerrit Jansen1, Philip S Low4, Adriaan A Lammertsma2 and Conny J van der Laken1*
Abstract
Introduction: Detection of (subclinical) synovitis is relevant for both early diagnosis and monitoring of therapy of
rheumatoid arthritis (RA). Previously, the potential of imaging (sub)clinical arthritis was demonstrated by targeting
the translocator protein in activated macrophages using (R)-[11C]PK11195 and positron emission tomography (PET).
Images, however, also showed significant peri-articular background activity. The folate receptor (FR)-b is a potential
alternative target for imaging activated macrophages. Therefore, the PET tracer [18F]fluoro-PEG-folate was
synthesized and evaluated in both in vitro and ex vivo studies using a methylated BSA induced arthritis model.
Methods: [18F]fluoro-PEG-folate was synthesized in a two-step procedure. Relative binding affinities of non-
radioactive fluoro-PEG-folate, folic acid and naturally circulating 5-methyltetrahydrofolate (5-Me-THF) to FR were
determined using KB cells with high expression of FR. Both in vivo [18F]fluoro-PEG-folate PET and ex vivo tissue
distribution studies were performed in arthritic and normal rats and results were compared with those of the
established macrophage tracer (R)-[11C]PK11195.
Results: [18F]fluoro-PEG-folate was synthesized with a purity >97%, a yield of 300 to 1,700 MBq and a specific
activity between 40 and 70 GBq/µmol. Relative in vitro binding affinity for FR of F-PEG-folate was 1.8-fold lower
than that of folic acid, but 3-fold higher than that of 5-Me-THF. In the rat model, [18F]fluoro-PEG-folate uptake in
arthritic knees was increased compared with both contralateral knees and knees of normal rats. Uptake in arthritic
knees could be blocked by an excess of glucosamine-folate, consistent with [18F]fluoro-PEG-folate being specifically
bound to FR. Arthritic knee-to-bone and arthritic knee-to-blood ratios of [18F]fluoro-PEG-folate were increased
compared with those of (R)-[11C]PK11195. Reduction of 5-Me-THF levels in rat plasma to those mimicking human
levels increased absolute [18F]fluoro-PEG-folate uptake in arthritic joints, but without improving target-to-
background ratios.
Conclusions: The novel PET tracer [18F]fluoro-PEG-folate, designed to target FR on activated macrophages
provided improved contrast in a rat model of arthritis compared with the accepted macrophage tracer (R)-[11C]
PK11195. These results warrant further exploration of [18F]fluoro-PEG-folate as a putative PET tracer for imaging
(sub)clinical arthritis in RA patients.
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Introduction
Activated macrophages infiltrate inflamed synovium of
rheumatoid arthritis (RA) patients in early stages of the
disease and play a pivotal role in sustaining the chronic
phase of RA [1,2]. Assessment of these synovial macro-
phages could provide a means to predict and monitor
clinical disease activity, since the number of synovial
macrophages correlates with disease activity scores and
response to treatment [1].
In a large subset of RA patients, clinical manifestations
of disease are preceded by a preclinical phase character-
ized by the presence of auto-immune antibodies and
presumably subclinical synovitis [3,4]. Visualization of
macrophages in subclinically inflamed synovium may
thus enable earlier initiation of therapy, which could
prevent the onset of joint damage. Moreover, RA
patients in remission may also benefit from detection of
subclinical synovitis, since joint damage has been
noticed in a substantial subset of these patients despite
clinically quiescent disease [5].
Advanced imaging techniques, such as positron emis-
sion tomography (PET), enable non-invasive visualization
of macrophages, but require availability of suitable radi-
oligands. Previously, feasibility of imaging (sub)clinical
arthritis was demonstrated using the macrophage target-
ing PET tracer (R)-[11C]PK11195 (1-[2-chlorophenyl]-N-
methyl-N-[1-methyl-propyl]-3-isoquinoline carboxamide),
that binds to the translocator protein that is up-regulated
in activated macrophages [6]. Due to background uptake
of this tracer in peri-articular tissue, however, detection
of subclinical synovitis may be suboptimal [6,7]. Conse-
quently, there is a need for other macrophage tracers
with lower background binding in peri-articular tissues.
A promising alternative target present on macro-
phages is the folate receptor (FR), to which both folic
acid and 5-methyltetrahydrofolate (5-Me-THF) bind
with high (nanomolar) affinity [8]. In addition, the num-
ber of normal tissues expressing FR is limited [9,10],
and overexpression has only been found on activated
macrophages and several (epithelial) cancer cells
[8,9,11,12]. Hence, the FR has been recognized as an
attractive molecular target for diagnostic as well as ther-
apeutic approaches [12-18].
Xia et al. [11] demonstrated that, in contrast to rest-
ing macrophages, activated macrophages at sites of
inflammation and infection express a functional b-iso-
form of FR. In addition, it was shown that FR-b is
expressed abundantly on macrophages in synovial tissue
of (clinically active) RA patients, providing opportunities
for targeting this disease with highly selective PET tra-
cers and folate antagonist drugs [12,13,15].
To date, various imaging procedures for targeting FR
have been developed [17-19]. Gamma scintigraphic ima-
ging with EC20, a 99mTc-labelled folate agent, has been
successfully applied for imaging of arthritis and infection
in preclinical studies and detection of arthritic joints in
RA patients [20-22]. As PET provides higher sensitivity
and spatial resolution, it is particularly interesting for
detection of subclinical arthritis.
In the present study, a novel FR targeting fluorine-18
labelled PET tracer, [18F]fluoro-polyethylene glycol
(PEG)-folate was developed. Several 18F-based folate tra-
cers have been synthesized thus far [23-26], but [18F]
fluoro-PEG-folate was anticipated to show improved
kinetics because of the introduction of the PEG moiety
[27]. Therefore, its characteristics were assessed in in
vitro FR binding studies and in ex vivo tissue distribu-
tion and in vivo PET studies using a methylated bovine
serum albumin (mBSA) induced arthritis model in
the rat.
Materials and methods
Synthesis of [18F]fluoro-PEG-folate and (R)-[11C]PK11195
[18F]fluoro-PEG-folate (1) was synthesized in a two-step
procedure (Figure 1): First, [18F]succinylfluorobenzoate
([18F]SFB, 4) was obtained by fluorination of the SFB
precursor (2) (ABX, Radeberg, Germany). The precursor
(5 mg) was dissolved in 1 mL acetonitrile and, after
standard work-up of the [18F]fluoride solution, the pre-
cursor was added and the reaction was allowed to pro-
ceed for 10 minutes at 90°C. The labeled precursor (3)
was then deprotected with 40 µL of tetrapropylammo-
nium hydroxide, and the reaction mixture was evapo-
rated and treated with tetramethyl-o-(N-succinimidyl)
uranium tetrafluoroborate to generate [18F]SFB (4). This
[18F]SFB solution was passed over a preconditioned (10
mL sterile ethanol 96% and then 10 mL water for injec-
tion) Waters Sep-Pak C18 cartridge (Milford, MA,
USA). After washing with 10 mL 15% acetonitrile in
water for injection and subsequent elution of the pro-
duct from the cartridge with 1.5 mL acetonitrile, the
[18F]SFB solution was evaporated to a volume of
approximately 100 µL. A solution of 2 mg PEG-folate
precursor (5) in 1 mL borate buffer (150 mM, pH 8.6)
was added to the 100 µL solution of [18F]SFB (4) in
acetonitrile and reacted for 30 minutes at ambient tem-
perature. The reaction mixture was injected onto a
Gemini 5µ C18 HPLC column (Phenomenex, Torrance,
CA, USA), which was eluted with an 80/20 mixture of
acetonitrile/0.1% trifluoroacetic acid in water at 3.0 mL/
minute and UV at 280 nm. The product, [18F]fluoro-
PEG-folate, eluted at 31 to 33 minutes. This fraction
was collected in 30 mL water and passed over a precon-
ditioned (10 mL sterile ethanol 96% and then 10 mL
water for injection) Waters Sep-Pak tC18 (Milford, MA,
USA). After washing with 20 mL water for injection, the
product was eluted from the cartridge with 1.0 mL ster-
ile ethanol (96%) and 14 mL of a sterile and pyrogen
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free sodium phosphate solution (7.09 mM, pH 5.4) in
saline. The final mixture was passed over a Millex GV
0.22 µm filter (Millipore, Billerica, MA, USA), yielding a
sterile, isotonic and pyrogen free solution of 0.5-1.5 GBq
of [18F]fluoro-PEG-folate. The product was analyzed
using HPLC on a Varian ChromSpher 5 C18 column
(Lake Forest, CA, USA), which was eluted with a 20/80
mixture of acetonitrile/0.1% trifluoroacetic acid in water
at 1.2 mL/minute and UV at 280 nm.
(R)-[11C]PK11195 was synthesized routinely with a
radiochemical purity >98% and mean specific activity of
95.7 ± 28.4 GBq/μmol, as described previously [28].
In vitro FR binding competition assay
In vitro FR binding competition assays were performed
essentially as described previously [12]. In short, FR
expressing human KB cells grown in folate deficient RPMI
medium (Buffalo, NY, USA) were detached by trypsiniza-
tion and washed twice in ice-cold Hepes-buffered saline
solution (pH 7.4) at a density of 1 × 106 cells/mL. Next,
100 µL of this cell suspension was incubated with folate-
fluorescein isothiocyanate (FITC) [11] to a final concentra-
tion of 10 nM in the absence or presence of a 0.1- to 100-
fold molar excess of unlabelled folic acid, 5-Me-THF
(Merck Eprova, Schaffhausen, Switzerland) or unlabelled,
non-radioactive reference compound fluoro-PEG-folate.
Following 15 minutes of incubation at 4#176;C, cells were
centrifuged and analyzed for displacement of folate-FITC
binding by flow cytometric analysis (FACS Scan, BD Bios-
ciences, San Jose, CA, USA).
Animals
Wistar rats (male, body weight approximately 200 to 300
g, Charles River International Inc., Sulzfeld, Germany)
were provided with standard food (16% protein rodent
diet, Harlan Laboratories Inc., Madison, WI, USA) and
water ad libitum. Rats were housed in groups of four in
conventional cages kept in a room with a 12-hour light/
dark cycle and constant room temperature (21ºC) and
humidity level (50%). For experiments designed to reduce
plasma folate levels, arthritic rats were housed in cages
with a grid floor to prevent folate intake from feces and
were fed ad libitum with folate deficient chow (Arie Blok
BV, Woerden, The Netherlands).
All animal experiments were performed in accordance
with the Dutch law on animal experimentation and
were approved by the committee on animal experimen-
tation of the VU Medical Center.
Induction of knee arthritis and study timelines
Antigen induced arthritis was generated as described pre-
viously [29] with adaptations for optimal PET imaging of
Figure 1 Synthesis of [18F]fluoro-PEG-folate. Synthesis of [18F]fluoro-PEG-folate. Conditions: i: [18F]fluoride, acetonitrile, K[2.2.2], K2CO3, 90°C, 10
minutes; ii: a: tetrapropylammonium hydroxide, b: tetramethyl-o-(N-succinimidyl)uranium tetrafluoroborate, 30 to 50% (for i and ii); iii: 150 mM
borate buffer, 30 minutes ambient temperature, 70 to 90%.
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arthritis. Briefly, rats were immunized subcutaneously at
Days 0 and 7 with 200 μL of a solution of 50 mg mBSA
(Sigma-Aldrich Chemie BV, Zwijndrecht, The Nether-
lands) dissolved in 1 mL 0.9% NaCl and emulsified in 1
mL complete Freund’s adjuvant (Sigma-Aldrich, Stein-
heim, Germany) and 1 mL custom Bordetella pertussis
antigen (Becton Dickinson, Breda, The Netherlands). To
induce local arthritis (Day 20), rats received an intra-
articular injection in the right knee with 60 μL of a solu-
tion of 10 mg mBSA in 1 mL 0.9% NaCl. At Day 27,
PET scans were performed. Immediately after PET scan-
ning, rats were sacrificed and ex vivo tissue distribution
of the tracers was measured.
PET scanning protocol
Scans were performed using a double LSO/LYSO layer
ECAT High Resolution Research Tomograph (HRRT,
CTI/Siemens, Knoxville, TN, USA), a small animal and
human brain 3-dimensional (3D) scanner with high spa-
tial resolution (2.3 to 3.4 mm full width at half maxi-
mum) and high sensitivity [30]. Arthritic rats (n = 4) or
normal rats (n = 7) were anesthetized (approximately
2% isoflurane with an oxygen flow of 0.6 to 0.8 L/min)
and positioned in the HRRT. A static transmission scan
(using a rotating 740 MBq 137Cs point source) of six
minutes duration was performed and following intrave-
nous injection of 15.1 ± 3.2 MBq [18F]fluoro-PEG-folate
via a jugular vein canula, an emission scan was acquired
for one hour. PET data were normalized and corrected
for scatter, randoms, attenuation, decay and dead time.
Data were converted into 16 sinograms (5 × 5, 5 × 10, 3
× 15, 2 × 30, 2 × 60, 2 × 150, 2 × 300, 1 × 600, 2 × 900
s). Images were reconstructed using an iterative 3D
ordinary Poisson ordered-subsets expectation-maximiza-
tion algorithm with 8 iterations and 16 subsets. Result-
ing images had a matrix size of 256 × 256 × 207 voxels,
each with a dimension of 1.21 × 1.21 × 1.21 mm3.
PET image analysis
PET images were processed using AMIDE software
(Amide’s a Medical Image Data Examiner, version 0.9.2)
[31]. Ellipsoid regions of interest (ROI) (6 × 17.7 × 7.4
mm3) were manually drawn over left and right knees.
ROIs were projected onto the dynamic image sequence,
thereby generating time-activity curves, expressed as
standardized uptake values (SUV), where SUV repre-
sents mean ROI radioactivity concentration normalized
for injected dose and body weight. For determining [18F]
fluoro-PEG-folate uptake in both knees, SUV was aver-
aged over the period from 50 to 60 minutes post-injec-
tion. Blood concentrations, also expressed as SUV, were
obtained from manually drawn ROIs (4 planes, 12 vox-
els/plane) in the heart. The image derived injected dose
(IDID) was obtained from a ROI covering the whole rat.
Ex vivo tissue distribution studies
Sixty minutes after intravenous injection of 15.1 ± 3.2
MBq [18F]fluoro-PEG-folate or 10.5 ± 2.9 MBq (R)-[11C]
PK11195, blood was collected from anesthetized rats by
heart puncture. Subsequently, rats were sacrificed by
cervical dislocation. Both knees (in toto), bone obtained
from the right hind leg, and blood and tissue from var-
ious internal organs were excised and weighed. Radioac-
tivity in each tissue (in percentage injected dose per
gram of tissue; %ID/g) was determined using an LKB
1282 Compugamma CS gamma counter (LKB Wallac,
Turku, Finland). Tissue distribution studies were per-
formed in four arthritic rats and eight normal rats for
[18F]fluoro-PEG-folate and in five arthritic rats for
(R)-[11C]PK11195.
Histopathology and immunohistochemistry
Both knees were dissected in toto, fixed (10% parafor-
maldehyde, 2% sucrose/phosphate buffered saline,
pH 7.3) for seven days at 4ºC and decalcified in
122.8 mM sodium ethylenediaminetetraacetic acid
(Na2-EDTA.2H2O) (Merck, Darmstadt, Germany) and
112.5 mM sodium hydroxide (NaOH) (pH 7.2), (Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands) for
approximately seven weeks at 4ºC. After rinsing, knees
were processed for paraffin embedding. Sagittal sections
(5 µm) from the center of the joint were used for immu-
nohistochemical staining of macrophages with a mouse
anti-rat monoclonal antibody ED1 (MCA341R, Serotec,
Düsseldorf, Germany), that recognizes the rat homolo-
gue of human CD68 [32]. Briefly, after antigen retrieval
with a solution of 0.1% pepsin (Sigma-Aldrich Chemie
BV, Zwijndrecht, The Netherlands), 0.1% of HCl 37% in
phosphate buffered saline (PBS) per slide for 30 minutes
at 37ºC, sections were incubated for 1 hour with 1:100
diluted ED1 antibody in 0.1% BSA/PBS. The detection
EnVision™ kit (K4063 dual-link-HRP rabbit/mouse,
DAKO, Glostrup, Denmark) was used according to the
instructions of the manufacturer. After washing with
PBS, slides were stained for peroxidase activity with 3.3’-
diaminobenzidine tetrahydrochloride containing 0.01%
H2O2. Subsequently, sections were counterstained with
hematoxylin, dehydrated and mounted. Negative con-
trols were included by replacement of the primary anti-
body with 1% BSA/PBS. Images were captured by using
a Leica 4000B microscope and Leica digital camera
DC500 (Microsystems B.V., Rijswijk, The Netherlands).
In vivo blockade of FR
In order to investigate whether [18F]fluoro-PEG-folate
binds specifically to FR, blocking studies were performed
in rats (n = 6) by pre-administration of a ≥100-fold molar
excess of the folate conjugate glucosamine-folate five min-
utes prior to the injection of [18F]fluoro-PEG-folate.
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Glucosamine-folate was preferred over folic acid because
of its increased solubility at low pH, preventing precipita-
tion in the kidneys [33]. PET and ex vivo tissue distribu-
tion studies were performed as described above.
Studies of rats with reduced plasma folate levels
Conceptually, high plasma and tissue levels of 5-Me-
THF, the naturally occurring form of folate, in rodents
(approximately 10-fold higher than in humans [34]) may
compete with [18F]fluoro-PEG-folate for binding to FR.
To investigate this, one subgroup of rats (n = 4) was fed
with folate deficient chow (Arie Blok BV, Woerden, The
Netherlands) for 14 days. Plasma 5-Me-THF levels were
determined by positive electrospray liquid chromatogra-
phy tandem mass spectrometry (LC-MS/MS) (Applied
Biosystems, Foster City, CA, USA) with a plasma intra-
assay CV <4% and inter-assay <2% [35].
Statistical analysis
Statistical tests were performed using SPSS version 15.0
for Windows (SPSS Inc., Chicago, IL, USA). A Wilcoxon
signed rank (exact) test was used to determine differ-
ences in paired observations, for example, uptake of
[18F]fluoro-PEG-folate in the arthritic versus contralat-
eral knee. Mann-Whitney (exact) tests were performed
to analyze differences in (a) [18F]fluoro-PEG-folate
uptake in arthritic versus normal knee, (b) [18F]fluoro-
PEG-folate versus (R)-[11C]PK11195 uptake, (c) [18F]
fluoro-PEG-folate uptake in the arthritic knee under
normal versus folate deficient conditions, and (d) tissue
uptake ratios. A P-value <0.05 was considered as statisti-
cally significant. Results are presented as mean ± stan-
dard deviation (SD), unless stated otherwise.
Results
Synthesis of [18F]fluoro-PEG-folate
[18F]fluoro-PEG-folate was synthesized via a two-step
radiochemical reaction sequence (Figure 1). The inter-
mediate [18F]SFB was obtained in 30 to 50% decay cor-
rected radiochemical yield, while the reaction with 3
was performed in 70 to 90% decay corrected radioche-
mical yield (Figure 1). Representative HPLC chromato-
grams are depicted in Additional file 1, Figure S1. The
procedure yielded 300 to 1,700 MBq of [18F]fluoro-PEG-
folate with a radiochemical purity >97% and a specific
activity of 40 to 70 GBq/µmol at the end of synthesis.
In vitro folate competition assay
In vitro binding competition assays with the FR expres-
sing KB cell line were performed to compare relative
binding affinities of fluoro-PEG-folate with that of folic
acid and the biologically active and circulating plasma
form of folate, 5-Me-THF. Figure 2A shows displace-
ment of folate-FITC from the receptor in the presence
of increasing concentrations of folic acid, unlabelled
fluoro-PEG-folate and 5-Me-THF. Relative binding affi-
nities were calculated from these studies indicating that
binding affinity for FR of fluoro-PEG-folate is 1.8-fold
lower than that of folic acid, but 3-fold higher than that
of 5-Me-THF (Figure 2B).
Presence of synovial macrophages in arthritic knees
Arthritis induced by intra-articular injection of mBSA in
the knees of immunized rats was characterized by influx
of macrophages in the synovium as shown by immuno-
histochemical staining (Figure 3A). In contrast, in the
contralateral control knee, macrophage infiltration was
minimal compared with the arthritic knee (Figure 3B).
PET studies
[18F]fluoro-PEG-folate images clearly visualized arthritis
(Figure 4A). SUV of [18F]fluoro-PEG-folate in arthritic
knees was markedly increased compared with that in
contralateral control knees (1.04 ± 0.06 vs 0.60 ± 0.06,
respectively) (Figure 4A) and in (right) knees of normal
rats (0.67 ± 0.07, P <0.01).
Knee time-activity curves of ROIs of arthritic knees and
contralateral knees showed that increased [18F]fluoro-
PEG-folate uptake in the arthritic knee was evident
rapidly after injection of the tracer and persisted for one
hour (Figure 4B), with a slightly increasing arthritic-to-
contralateral knee ratio over time (Figure 4C).
Blood [18F]fluoro-PEG-folate levels peaked in the first
minutes, but decreased within two minutes below the
level of the arthritic knee (see Additional file 2, Figure
S2A). The arthritic knee-to-blood ratio increased over
time, pointing to retention of the tracer in the arthritic
joint in the presence of clearance from the blood (see
Additional file 2, Figure S2B).
Ex vivo tissue distribution studies
[18F]fluoro-PEG-folate uptake (expressed as mean %ID/
g) in arthritic knees was increased compared with con-
tralateral knees (0.34 ± 0.08 vs 0.24 ± 0.08, respectively)
(Figure 5) and (right) knees of normal rats (0.16 ± 0.04,
P <0.01), thereby confirming the PET data.
[18F]fluoro-PEG-folate uptake was also observed in the
liver (0.36 ± 0.22), spleen (1.07 ± 0.45), intestine (0.72 ±
0.45) and kidneys (3.42 ± 0.47) (Figure 5). These obser-
vations were in line with the accumulation seen in PET
images (see Additional file 3, Figure S3A).
Tissue distribution of [18F]fluoro-PEG-folate was com-
pared with that of the established macrophage targeting
PET tracer (R)-[11C]PK11195. [18F]fluoro-PEG-folate
cleared more rapidly from blood than (R)-[11C]PK11195,
resulting in significantly lower blood levels of [18F]
fluoro-PEG-folate than of (R)-[11C]PK11195 (0.02 ± 0.02
vs 0.08 ± 0.01, respectively; P <0.05). Consequently,
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mean arthritic knee-to-blood ratios of [18F]fluoro-PEG-
folate were higher than those of (R)-[11C]PK11195 (23.1
± 14.3 vs 10.0 ± 1.9, respectively) (Figure 6). Mean abso-
lute uptake (%ID/gram) of [18F]fluoro-PEG-folate was
lower than that of (R)-[11C]PK11195 in various tissues
including arthritic knees (0.34 ± 0.08 vs 0.79 ± 0.05,
respectively; P <0.05), contralateral knees (0.24 ± 0.08 vs
0.57 ± 0.05, respectively; P <0.05) and other internal
organs, such as heart, lungs, spleen and gastrointestinal
organs (data not shown).
Mean arthritic-to-contralateral knee uptake ratios
of [18F]fluoro-PEG-folate (1.42 ± 0.15) and (R)-[11C]
PK11195 (1.39 ± 0.10) were similar. Nevertheless, with
peri-articular bone as the most relevant background tis-
sue, mean arthritic-to-ipsilateral bone ratios of [18F]
fluoro-PEG-folate (1.64 ± 0.15) were significantly higher
than those of (R)-[11C]PK11195 (1.14 ± 0.18, P <0.05)
(Figure 6).
Blocking studies
After in vivo blockade of the FR with a ≥100-fold molar
excess of glucosamine-folate, arthritis was no longer
visualized on PET images (see Additional file 3, Figure
S3B). In addition, a marked decrease in mean [18F]
A B 
Figure 2 FR-binding affinities. (A) Displacement of folate-FITC binding from human KB cells (10 nM, 4ºC) with increasing concentrations of
unlabelled folic acid, fluoro-PEG-folate and 5-Me-THF. (B) Relative binding affinities to FR of folic acid (set at 1) versus fluoro-PEG-folate and 5-
Me-THF. Results are presented in mean ± SEM of seven separate experiments.
A B 
Figure 3 Immunohistochemical staining for macrophages. Tissue sections (x200 magnification) of (A) arthritic and (B) contralateral knees
with anti-rat CD68 (ED1) staining (brown staining) for synovial macrophages. Arrows indicate examples of ED1 positive macrophages.
Gent et al. Arthritis Research & Therapy 2013, 15:R37
http://arthritis-research.com/content/15/2/R37
Page 6 of 11
fluoro-PEG-folate tracer uptake (%ID/gram) in the
arthritic knee (0.03 ± 0.02) was found in ex vivo tissue
distribution studies (Figure 5), indicating specific bind-
ing of the tracer to FR. Finally, reduced accumulation of
[18F]fluoro-PEG-folate was also observed in liver (0.06 ±
0.07) and spleen (0.02 ± 0.01), while uptake in kidneys
(1.52 ± 0.81) and intestines (0.24 ± 0.31) was reduced
but still appreciable.
C B   
Figure 4 [18F]fluoro-PEG-folate images and corresponding time-activity curves of arthritic and normal knees. (A) Example of [18F]fluoro-
PEG-folate image of arthritic rat at the level of the knees (L = left contralateral knee, R = right arthritic knee). (B) corresponding time-activity
curves (of ROI as indicated in 4A) of arthritic and contralateral knees. (C) Arthritic-to-contralateral knee ratio as function of time. Results are
presented as mean ± SD of four arthritic rats.
Figure 5 Tissue distribution of [18F]fluoro-PEG-folate. Tissue distribution of [18F]fluoro-PEG-folate in arthritic rats without (black bars) and with
(gray bars) pre-treatment with a ≥100-fold molar excess of glucosamine-folate. Results are presented as mean ± SD of four untreated and four
pre-treated rats.
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Effects of reducing plasma folate levels
Mean plasma serum levels in rats fed with folate deficient
chow for 14 days decreased from 110 ± 21 to 11.0 ± 4.3
nM (that is, comparable with human physiological levels).
Mean tissue radioactivity (%ID/gram) found in
arthritic knees of rats on folate deficient chow (0.52 ±
0.10) was increased compared with that of rats on nor-
mal chow (0.34 ± 0.08, P <0.05). Mean arthritic knee-to-
bone ratios (1.38 ± 0.17) did not improve under folate
deficient conditions, since uptake of the tracer in ipsilat-
eral bone tissue increased in parallel.
Discussion
In this study, the synthesis of the novel FR ligand [18F]
fluoro-PEG-folate was described. In addition, initial in
vitro and in vivo preclinical studies were performed that
showed that this ligand was suitable as a PET tracer for
imaging of arthritis.
The results of the in vitro binding studies showed high
binding affinity of fluoro-PEG-folate to FR present on
KB cells. KB cells, which overexpress FR-a, were used
as a model system since folic acid and derivatives bind
to both FR-a and FR-b (expressed on activated macro-
phages) with comparable affinity [36]. Accumulation of
the tracer in arthritic knee joints of rats was shown by
both in vivo PET scans and by ex vivo tissue distribution
studies. Specific binding of [18F]fluoro-PEG-folate to FR
in the macrophage-rich synovium was demonstrated by
in vivo blocking studies.
As a tracer, [18F]fluoro-PEG-folate shows promise, as
the lower peri-articular uptake in bone (marrow) and
the faster clearance from blood compared with (R)-[11C]
PK11195 provide improved contrast when imaging
arthritic joints. This will especially be important for the
imaging of subclinical disease activity.
The mBSA induced rat arthritis model is an established
model of RA, which resembles human pathology of RA
at the joint level [29]. A limitation of the rat model is the
small size of the arthritic knee joints and, hence, a very
small volume of inflamed synovia, which hampered exact
determination of tracer uptake in synovial tissue. The
spatial resolution and anatomical information provided
by the PET scanner were not sufficient for exact defini-
tion of synovial ROIs. Instead, an ROI was drawn on top
of the knee area, which also may include some peri-
articular bone (marrow). In addition, isolation of pure
synovium for ex vivo tissue distribution studies was not
feasible. Instead, the knee joint as a whole, including
some peri-articular soft tissue, was excised and prepared
for analysis. Both absolute uptake, arthritic joint-to-bone
(marrow) ratios and arthritic-to-contralateral knee ratios
of [18F]fluoro-PEG-folate may, therefore, have been
underestimated. Statistical significance of the differences
between uptake (ratios) of [18F]fluoro-PEG-folate and (R)-
[11C]PK11195, and between uptake in arthritic versus
control joints was further reduced due to lack of statisti-
cal power related to the relatively small numbers of ani-
mals (n = 4 to 8) per group.
Relatively high [18F]fluoro-PEG-folate uptake was
observed in the liver and spleen of rats with mBSA
induced arthritis, which was largely abolished by FR
receptor blockade with glucosamine-folate, suggesting
specific receptor binding of the tracer. Conceivably, this
observation may be explained by an increase of macro-
phage-like cells in the liver and spleen due to systemic
immune activation as part of locally antigen induced
arthritis [37,38]. Similarly, increased (specific) liver and
spleen uptake of the folate conjugate EC20 was noted in
rats with adjuvant induced arthritis compared to normal
rats [20,39]. Further corroboration was found in tissue
distribution studies, showing that uptake of [18F]fluoro-
PEG-folate in the liver and spleen were respectively 3.8
and 2.2 times higher in arthritic than in normal rats
(results not shown). Part of the liver and intestinal
uptake of the novel folate tracer was, however, not
blocked by glucosamine-folate, which could be due to
the hepatobiliary secretion of the tracer. Likewise, [18F]
fluoro-PEG-folate kidney uptake could be partly abol-
ished under FR-blockade conditions, which was antici-
pated from folate receptor expression in proximal
tubule cells, but leaving retention of the tracer in the
Figure 6 Target-to-background ratios of [18F]fluoro-PEG-folate.
Arthritic knee-to-bone and arthritic knee-to-blood ratios of [18F]
fluoro-PEG-folate (black bars) and (R)-[11C]PK11195 (grey bars)
obtained from ex vivo tissue distribution studies. Results are
presented as mean ± SD of four rats for [18F]fluoro-PEG-folate and
five rats for (R)-[11C]PK11195. *= P <0.05
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kidney, possibly due to renal clearance. Additionally,
non-specific tissue uptake of [18F]fluoro-PEG-folate or
radiometabolite formation could also have influenced
tissue distribution studies.
The ultimate value of [18F]fluoro-PEG-folate for ima-
ging of RA has to be corroborated in human studies,
which is readily achievable since the current method for
the synthesis of [18F]fluoro-PEG-folate can easily be
translated into a Good Manufacturing Practice compliant
method yielding a clinical grade [18F]fluoro-PEG-folate
radiotracer. Since human 5-Me-THF plasma and tissue
levels are substantially lower compared to rat it is concei-
vable that absolute uptake of [18F]fluoro-PEG-folate in
inflamed joints may be higher in humans. Nevertheless,
simultaneously increased background uptake of [18F]
fluoro-PEG-folate was shown in rats fed with folate defi-
cient chow. Furthermore, it should be acknowledged that
humans exhibit generally higher FR expression levels in
the kidneys compared to rats [10], which could lead to
higher accumulation of [18F]fluoro-PEG-folate in human
patients than was found in our experiments performed in
rats. Thus, it remains to be seen whether lower circulat-
ing 5-Me-THF plasma levels and generally higher FR
expression tissue levels in humans set favorable condi-
tions for [18F]fluoro-PEG-folate PET imaging of RA.
Currently, the single-photon emission computed
tomography (SPECT) imaging agent 99mTc-EC20 is the
only FR-targeting radioligand that has been used for
clinical applications in RA patients [22]. 99mTc-EC20
was safely applied and targeted to inflamed joints.
Although SPECT may be a cheaper alternative, PET
imaging provides higher sensitivity and spatial resolution
and allows signal quantification. Given the notion that
the FR has also been recognized as an important target
for (image guided) delivery of therapeutics, FR-based
PET imaging could be exploited to select patients who
would benefit from FR mediated targeting of activated
macrophages by antifolates [12]. The folate antagonist
methotrexate (MTX) is the most frequently prescribed
disease modifying antirheumatic drug for RA, but side
effects and resistance to MTX often occur [40]. MTX
exhibits a relatively low binding affinity for FR, hence
more selective targeting of folate antagonists to FR
expressing cells in the synovium may be of value if ther-
apy with MTX fails [12]. Other therapy strategies could
include folate-immunoconjugates [41] and folate-conju-
gated vincristine [42].
Finally, imaging of macrophages with folate radiotra-
cers can also be used for other diseases with macro-
phage activation [43,44]. For example, visualization of
activated macrophages in atherosclerosis may be of
value in patients at increased cardiovascular risk, which
includes RA patients [45].
Conclusions
In conclusion, highly sensitive arthritis imaging by PET
and macrophage targeting using the novel [18F]fluoro-
PEG-folate tracer was demonstrated in an mBSA
induced arthritis model in rats. [18F]fluoro-PEG-folate
shows higher contrast due to a lower background signal
than the established, clinically available macrophage tra-
cer (R)-[11C]PK11195. These promising results set the
stage for proof of concept studies in RA patients.
Additional material
Additional file 1, Figure S1: Representative HPLC chromatograms of
the purification and analysis of [18F]fluoro-PEG-folate. (A) Semi prep HPLC
chromatogram of the purification of [18F]fluoro-PEG-folate; top: UV
detection, bottom: radioactivity detection. The product elutes at 31 to 33
minutes, radiochemical yield, calculated from this chromatogram is 73%.
The non-radioactive reference compound eluted at the same retention
time as the radioactive compound (result not shown) (B) Analysis (quality
control) of the final solution of [18F]fluoro-PEG-folate; top: UV detection,
bottom: radioactivity detection. Radiochemical purity >99%. (C) Analysis
(quality control) of the final solution of [18F]fluoro-PEG-folate, with the
addition of reference compound; top: UV detection, bottom: radioactivity
detection. The reference compound elutes at the same time as [18F]
fluoro-PEG-folate and confirms the identity of [18F]fluoro-PEG-folate.
Additional file 2, Figure S2: Uptake [18F]fluoro-PEG-folate in arthritic
knee and blood. (A) Time-activity curves of [18F]fluoro-PEG-folate uptake
in arthritic knee and blood. (B) Arthritic knee-to-blood ratio as function
of time. Results are presented as mean ± SD of four arthritic rats.
Additional file 3, Figure S3: [18F]fluoro-PEG-folate imaging of arthritic
rats. [18F]fluoro-PEG-folate uptake in the right arthritic knee at (A)
baseline (arrow) and (B) after blocking the FR with an excess dose of
glucosamine-folate. In the latter case abolishment of the signal in the
arthritic knee is evident.
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